Long-term effectiveness and safety of dupilumab treatment in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the BioDay registry

Marie Louise A. Schuttelaar, Celeste M. Boesjes, Junfen Zhang, Laura Loman, Esmé Kamphuis, Lian F. van der Gang, Lisa P. van der Rijst, Lotte S. Spekhorst, C. Dekkers, Geertruida L. E. Romeijn, N. Peter A. Zuithoff, Inge Haeck, Marijke Kamsteeg, A. J. Oosting, Antoni Gostynski, A. M. T. van Lynden-van Nes, Ron A. Tupker, A. van Tuyll van Serooskerken, A. Flinterman, Klaziena PolitiekW. R. H. Touwslager, Wianda A. Christoffers, S. M. Stewart, Marlies de Graaf, M. S. de Bruin-Weller

Research output: Contribution to journalMeeting AbstractAcademic

Abstract

Introduction: Limited data is available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice.

Objectives: To evaluate effectiveness and safety of dupilumab treatment in AD patients up to 5 years in daily practice.

Methods: Data were extracted from the prospective, multicenter BioDay registry (October 2017–October 2022/December 2022) of patients with moderate-to-severe AD treated with dupilumab.

Results: In a study on clinical outcomes, 1286 patients were included (n = 130 children; n = 1025 adults; n = 131 elderly). The median follow-up time was 87.5 weeks (inter-quartile range (IQR) 32.0–157.0). Most patients maintained controlled AD with Eczema Area and Severity Index (EASI) ≤ 7 varying between 78.6–92.3% up to 5 years, while up to 70.5% of patients prolonged the dupilumab interval to mostly every 3/4 weeks. Significant differences in effect over time between age groups were found for EASI and Investigator Global Assessment (p = 0.046 and p = 0.010, respectively), however differences were rather small. In total, 306 patients (23.8%) discontinued dupilumab after a median of 54.0 weeks (IQR 29.0–110.00) with adverse events (AEs) (n = 98, 7.6%) and ineffectiveness (n = 85, 6.6%) as most frequently reported reasons.

In the Patient Reported Outcome Measures (PROMs) study, 1223 patients were included (n = 115 children; n = 1108 adults). After ≥1 year of treatment, mean Patient-Oriented Eczema Measure, Dermatology Life Quality Index, Numeric rating scale-pruritus ranged between 7.8–8.7, 3.5–4.2, and 2.9–3.1 in adults, respectively, whilst these PROMs ranged between 8.9–10.9, 4.4–6.4, and 3.0–3.7 in children, respectively. Of all patients, 66.8% reported ≥1 AE, with conjunctivitis being the most common (33.7%).

Conclusion: Up to 5 years, dupilumab maintained its effectiveness while two-thirds of the patients tapered to an interval of every 3/4 weeks. Treatment was discontinued in 23.8% of the patients mainly due to AEs and/or ineffectiveness. Overall, dupilumab showed a favourable safety profile. Additionally, dupilumab has demonstrated sustained effectiveness across various PROMs.
Original languageEnglish
Pages (from-to)43
Number of pages1
JournalContact Dermatitis
Volume91
Issue numberSupplement 1
DOIs
Publication statusPublished - 3-Sept-2024
Event16th Congress of the European Society Contact Dermatitis - Dresden, Germany
Duration: 4-Sept-20247-Sept-2024

Fingerprint

Dive into the research topics of 'Long-term effectiveness and safety of dupilumab treatment in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the BioDay registry'. Together they form a unique fingerprint.

Cite this